Supplementary Table 6. Sensitivity analysis on the effect modification by TBIL in participants without anemia

Outcome	Group	N	n (%)	Adj. OR/cOR (95% CI)*	*P*	*P* for interaction
Presence of CSVD (Wardlaw)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,172	234 (20.0)	Ref.		0.064
	Hypertension	894	360 (40.3)	1.84 (1.38–2.44)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	443	121 (27.3)	Ref.		
	Hypertension	357	151 (42.3)	1.08 (0.69–1.70)	0.737	
Presence of CSVD (Rothwell)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,172	352 (30.0)	Ref.		0.083
	Hypertension	894	478 (53.5)	1.81 (1.39–2.36)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	443	160 (36.1)	Ref.		
	Hypertension	357	189 (52.9)	1.09 (0.71–1.67)	0.701	
Total CSVD burden (Wardlaw)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,172		Ref.		0.136
	Hypertension	894		1.82 (1.38–2.41)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	443		Ref.		
	Hypertension	357		1.20 (0.78–1.86)	0.403	
Modified total CSVD burden (Rothwell)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,172		Ref.		0.096
	Hypertension	894		1.81 (1.40–2.32)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	443		Ref.		
	Hypertension	357		1.17 (0.78–1.75)	0.448	

Participants with anemia were excluded. Anemia in adults was defined as hemoglobin levels of <13 g/dL in males and <12 g/dL in females. All models were adjusted for age, sex, body mass index, current smoking, current drinking, diabetes, dyslipidemia, antihypertensive medication, antiplatelet medication, anticoagulant medication, and alanine aminotransferase and aspartate aminotransferase levels.

TBIL, total bilirubin; Adj., adjust; OR, odds ratio; cOR, common odds ratio; CI, confidence interval; CSVD, cerebral small vessel disease; Ref., reference.

*The association of hypertension with the presence of CSVD was evaluated using OR, while with CSVD burden was evaluated using cOR. The product term of the hypertension state and TBIL group was included in the model to assess the effect modification by TBIL; †Presence of CSVD was defined as total CSVD or modified total CSVD burden scores ≥1; ‡Total and modified total CSVD burdens were classified as grade 0 (total or modified total CSVD burden score 0), grade 1 (total or modified total CSVD burden score 1), grade 2 (total or modified total CSVD burden score 2–3), or grade 3 (total or modified total CSVD burden score ≥4).

https://doi.org/10.5853/jos.2025.01935